14 Months After U.S. FDA Charged India's Lupin, Manufacturing Facility At Mandideep Cleared
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - A long trail of hair splitting audits and investigations came to an end for India's drug maker Lupin as U.S. FDA issued an "All Clear" statement for the company's Mandideep manufacturing site in the central Indian state of Madhya Pradesh
You may also be interested in...
Mix-up Of Two Anti-Hypertension Drugs Sold In U.S. Prompts India's Lupin To Recall Product
MUMBAI - One of India's leading pharmaceutical companies Lupin Laboratories Ltd. has initiated a recall of its key ACE inhibitor lisinopril. Lupin had U.S. sales of roughly $45 million from the single drug, said a source closely tracking the news
Mix-up Of Two Anti-Hypertension Drugs Sold In U.S. Prompts India's Lupin To Recall Product
MUMBAI - One of India's leading pharmaceutical companies Lupin Laboratories Ltd. has initiated a recall of its key ACE inhibitor lisinopril. Lupin had U.S. sales of roughly $45 million from the single drug, said a source closely tracking the news
EU Proposes Recall Of Clopidogrel Because Of GMP Failures At Indian Glochem
Swiss company Acino Pharma says it is unnecessary to recall its generic clopidogrel products from the EU market, even though its Indian API supplier, Glochem Industries, failed a good manufacturing practices inspection